Comparison · NCT03355664-a59f8cd5
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Number of Severe Adverse Events by Study Arm
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Number of Severe Adverse Events by Study Arm. Trial comparisons, record NCT03355664-a59f8cd5. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03355664-a59f8cd5
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.013 | 0.00357 | 0.0461 | wilson | |
| Risk in group 2 | 0.0321 | 0.0138 | 0.0728 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0191 | -0.0609 | 0.0188 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.405 | 0.0798 | 2.06 | log | |
| Odds ratio, group 1 over group 2 | 0.397 | 0.0759 | 2.08 | log | |
Number needed to treat, for one fewer participant with the outcome on Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 than on Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 52.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | ACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24 | 2 | 154 | OG000 |
| Group 2 | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | TACT: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24 | 5 | 156 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Severe Adverse Events by Study Arm
- Description
All numerators in AE tables mean that the AE was reported as present according to the definitions defined in the US government DAIDS 2017 grading tables for reporting of adverse events. The AEs are reported without grading in this table, but are graded in the paper reporting this clinical trial.~All Primary analyses are reported (also in the accepted manuscript) along with the secondary outcomes needed to support the primary analysis. Secondary outcomes not involving the randomised comparison will be updated when the analyses are available. Please note that analyses of these Secondary outcomes will take time.
- Time frame
- 42 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
- NCT number
- NCT03355664
- Phases
- PHASE3
- Conditions
- Malaria, Falciparum
- Interventions
- ACT, TACT
- Lead sponsor
- University of Oxford
- Results first posted
- 2022-07-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03355664?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03355664-a59f8cd5